首页|Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia
Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
维普
AIM:To compare efficacy of proton pump inhibitors (PPIs) with H2-receptor antagonists (H2RAs) plus prokinetics (Proks) for dysmotility-like symptoms in functional dyspepsia (FD).METHODS:Subjects were randomized to receive openlabel treatment with either rabeprazole 10 mg od (n =57) or famotidine 10 mg bid plus mosapride 5 mg tid (n =57) for 4 wk.The primary efficacy endpoint was change (％) from baseline in total dysmotility-like dyspepsia symptom score.The secondary efficacy endpoint was patient satisfaction with treatment.RESULTS:The improvement in dysmotility-like dyspepsia symptom score on day 28 was significantly greater in the rabeprazole group (22.5％ ± 29.2％ of baseline)than the famotidine + mosapride group (53.2％ ±58.6％ of baseline,P ＜ 0.0001).The superior benefit of rabeprazole treatment after 28 d was consistent regardless of Helicobacter pylori status.Significantly more subjects in the rabeprazole group were satisfied or very satisfied with treatment on day 28 than in the famotidine + mosapride group (87.7％ vs 59.6％,P =0.0012).Rabeprazole therapy was the only significant predictor of treatment response (P ＜ 0.0001),defined as a total symptom score improvement ≥ 50％.CONCLUSION:PPI monotherapy improves dysmotility-like symptoms significantly better than H2RAs plus Proks,and should be the treatment of first choice for Japanese FD.
NETL
NSTL
万方数据
维普
